bpc 157 for carpal tunnel: Frequently asked questions

Taper rather than stopping abruptly. If symptoms improve at week 4–6, continue daily dosing for another 2–4 weeks to consolidate tissue healing. Nerve remyelination is incomplete at the point symptoms resolve. Then taper to every-other-day dosing for 1–2 weeks before stopping entirely. This reduces the risk of symptom rebound if underlying inflammation hasn't fully resolved. If symptoms return within 2–3 weeks after stopping, resume at the original dose and consider extending the cycle to 12 weeks.

Check peptide storage and reconstitution first. Temperature excursions, contamination, or expired bacteriostatic water can render the peptide inactive without visible signs. If storage is confirmed correct, consider increasing dose to 500 mcg daily (upper end of typical range) or switching to twice-daily injections (250 mcg morning and evening). Nerve regeneration timelines vary. Some people require 6–8 weeks to notice changes. If no improvement after 8 weeks at 500 mcg daily, the peptide is either ineffective for your condition or your carpal tunnel severity requires surgical intervention.

Rotate injection sites every 2–3 days to avoid tissue irritation. Common sites include the abdomen (2 inches from navel), outer thigh, and volar forearm. Bruising occurs when the needle punctures a small capillary. It's cosmetic and resolves within 5–7 days. Apply light pressure with gauze immediately after injection (don't rub). If irritation persists (redness, warmth, swelling beyond 24 hours), discontinue use and inspect the vial for contamination. Cloudy solution or visible particles indicate bacterial growth.

Store lyophilized BPC-157 at −20°C in a desiccated environment. Exposure to moisture or temperature fluctuations above 8°C before reconstitution degrades peptide bonds irreversibly. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Peptide degradation doesn't change the solution's appearance. Potency loss is invisible without HPLC analysis, which means improper storage creates a compound that looks identical but lacks therapeutic effect.

Direct extrapolation from animal studies to human dosing without allometric scaling overcalculates required doses by 600–800%. A rat study using 10 micrograms per kilogram translates to approximately 1.6 micrograms per kilogram in humans using FDA body surface area conversion. Not 10 micrograms per kilogram. Researchers using human-equivalent doses must apply the conversion factor (human dose = animal dose × [animal weight/human weight]^0.67) to avoid administering supraphysiologic amounts that exceed what safety studies support.

Animal models show diminished regenerative response when BPC-157 administration begins more than 7 days post-injury. Chronic demyelination and fibrotic tissue formation create a microenvironment resistant to growth factor signaling. Carpal tunnel cases with severe thenar atrophy, constant numbness, or abnormal two-point discrimination on clinical exam likely represent chronic nerve damage beyond the acute compression window where BPC-157 shows maximal effect in research. Surgical decompression may be the only intervention that restores space for nerve recovery in advanced cases.